Published in
Taylor and Francis Group, OncoImmunology, 1(4), p. e955683
DOI: 10.4161/21624011.2014.955683
Links
- ORCID
- Taylor and Francis Group | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma
Journal article published in 2015 by
Henning Zelba,
Benjamin Weide,
Alexander Martens,
Jithendra Kini Bailur,
Claus Garbe 
,
Graham Pawelec
,
Graham Pawelec
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
The melanoma-associated antigens Melan-A and NY-ESO-1 stimulate different T-cell responses in late-stage melanoma patients. Either CD4+ or CD8+ T-cell reactivity against NY-ESO-1 was associated with better prognosis, but for Melan-A, only CD8+ but not CD4+ T-cell responses were associated with longer survival.